These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration. Roberts JA; Udy AA; Bulitta JB; Stuart J; Jarrett P; Starr T; Lassig-Smith M; Roberts NA; Dunlop R; Hayashi Y; Wallis SC; Lipman J J Antimicrob Chemother; 2014 Sep; 69(9):2508-16. PubMed ID: 24879665 [TBL] [Abstract][Full Text] [Related]
4. Steady-State Ceftazidime-Avibactam Serum Concentrations and Dosing Recommendations in a Critically Ill Patient Being Treated for Pseudomonas aeruginosa Pneumonia and Undergoing Continuous Venovenous Hemodiafiltration. Soukup P; Faust AC; Edpuganti V; Putnam WC; McKinnell JA Pharmacotherapy; 2019 Dec; 39(12):1216-1222. PubMed ID: 31596506 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltration. Fuhrmann V; Schenk P; Jaeger W; Miksits M; Kneidinger N; Warszawska J; Holzinger U; Kitzberger R; Thalhammer F J Antimicrob Chemother; 2007 Nov; 60(5):1085-90. PubMed ID: 17855725 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. Fuhrmann V; Schenk P; Jaeger W; Ahmed S; Thalhammer F J Antimicrob Chemother; 2004 Oct; 54(4):780-4. PubMed ID: 15347636 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of amphotericin B lipid complex in critically ill patients undergoing continuous venovenous haemodiafiltration. Malone ME; Corrigan OI; Kavanagh PV; Gowing C; Donnelly M; D'Arcy DM Int J Antimicrob Agents; 2013 Oct; 42(4):335-42. PubMed ID: 23920093 [TBL] [Abstract][Full Text] [Related]
8. Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients. Traunmüller F; Schenk P; Mittermeyer C; Thalhammer-Scherrer R; Ratheiser K; Thalhammer F J Antimicrob Chemother; 2002 Jan; 49(1):129-34. PubMed ID: 11751776 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Malone RS; Fish DN; Abraham E; Teitelbaum I Antimicrob Agents Chemother; 2001 Nov; 45(11):3148-55. PubMed ID: 11600370 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients. Robatel C; Decosterd LA; Biollaz J; Eckert P; Schaller MD; Buclin T J Clin Pharmacol; 2003 Dec; 43(12):1329-40. PubMed ID: 14615469 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. Fish DN; Teitelbaum I; Abraham E Antimicrob Agents Chemother; 2005 Jun; 49(6):2421-8. PubMed ID: 15917542 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients. Guenter SG; Iven H; Boos C; Bruch HP; Muhl E Pharmacotherapy; 2002 Feb; 22(2):175-83. PubMed ID: 11837556 [TBL] [Abstract][Full Text] [Related]
13. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients. Isla A; Gascón AR; Maynar J; Arzuaga A; Toral D; Pedraz JL Clin Ther; 2005 May; 27(5):599-608. PubMed ID: 15978309 [TBL] [Abstract][Full Text] [Related]